原发性硬化性胆管炎特异性患者报告结局量表的开发与验证:PSC PRO
开发并外部验证含42个条目、分症状与症状影响两个模块的原发性硬化性胆管炎(PSC)特异性患者报告结局量表PSC PRO;102例PSC患者完成量表及SF-36、CLDQ、PBC-40、5-D瘙痒量表,显示良好信度与结构效度;作者结论为初步验证提示心理测量学性质良好,仍需在更大更多样样本中进一步验证。
要点
- PSC PRO含42个条目、两个模块(症状与症状影响),为自评量表,按美国食品药品监督管理局指南开发。
- 内部一致性Cronbach α为0.84-0.94,42个条目中41个与自身领域相关性最高。
- PSC PRO可区分有无肝硬化、肝硬化严重程度及有无抑郁史(P<0.05),但不能区分有无炎症性肠病(P>0.05)。
核心结论
- PSC PRO是按美国食品药品监督管理局指南开发的自评疾病特异性量表,本初步验证研究提示其心理测量学性质良好。
- 作者指出仍需在更大、更多样的PSC患者样本中进一步验证该量表。
研究设计与样本
- 开发含42个条目、分症状与症状影响两个模块的PSC特异性患者报告结局量表PSC PRO,并进行外部验证。
- 共102例PSC患者(44±13岁;32%男性,74%在职,39%肝硬化,14%有失代偿期肝硬化史,38%有抑郁史,68%有炎症性肠病)完成PSC PRO及其他量表。
- 信度与效度用临床数据和SF-36、CLDQ、PBC-40、5-D瘙痒量表评估;重测信度在重复填写PSC PRO的患者亚组中评估。
主要发现
- 内部一致性Cronbach α为0.84-0.94,42个条目中41个与自身领域相关性最高。
- PSC PRO各领域与SF-36、CLDQ、PBC-40相关领域相关性良好(R=0.69-0.90;均P<0.0001),与5-D瘙痒相关性较低(R=0.31-0.60;P<0.001)。
- 结构效度显示PSC PRO可按有无肝硬化、肝硬化严重程度及有无抑郁史区分患者(P<0.05),但不能按有无炎症性肠病区分(P>0.05)。
- 53例受试者在中位37(四分位距27-47)天内重复填写PSC PRO,多数领域组内相关系数为0.71-0.88(均P<0.001)。
关键数值与推荐
- 42个条目的PSC PRO含症状与症状影响两个模块,为自评量表,按美国食品药品监督管理局指南开发。
- 内部一致性Cronbach α为0.84-0.94;42个条目中41个与自身领域相关性最高。
- 与SF-36、CLDQ、PBC-40相关领域R=0.69-0.90(均P<0.0001),与5-D瘙痒R=0.31-0.60(P<0.001)。
- 重测信度组内相关系数0.71-0.88(均P<0.001),重测间隔中位37(四分位距27-47)天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出本研究为初步验证研究,仍需在更大、更多样的PSC患者样本中进一步验证该量表。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC-specific patient-reported outcome (PRO) instrument. We developed a 42-item PSC PRO instrument that contains two modules (Symptoms and Impact of Symptoms) and conducted an external validation. Reliability and validity were evaluated using clinical data and a battery of other validated instruments. Test-retest reliability was assessed in a subgroup of patients who repeated the PSC PRO after the first administration. One hundred two PSC subjects (44 ± 13 years; 32% male, 74% employed, 39% with cirrhosis, 14% with a history of decompensated cirrhosis, 38% history of depression, and 68% with inflammatory bowel disease [IBD]) completed PSC PRO and other PRO instruments (Short Form 36 V2 [SF-36], Chronic Liver Disease Questionnaire [CLDQ], Primary Biliary Cholangitis - 40 [PBC-40], and five dimensions [5-D Itch]). PSC PRO demonstrated excellent internal consistency (Cronbach alphas, 0.84-0.94) and discriminant validity (41 of 42 items had the highest correlations with their own domains). There were good correlations between PSC PRO domains and relevant domains of SF-36, CLDQ, and PBC-40 (R = 0.69-0.90; all P < 0.0001), but lower (R = 0.31-0.60; P < 0.001) with 5-D Itch. Construct validity showed that PSC PRO can differentiate patients according to the presence and severity of cirrhosis and history of depression (P < 0.05), but not by IBD (P > 0.05). Test-retest reliability was assessed in 53 subjects who repeated PSC PRO within a median (interquartile range) of 37 (27-47) days. There was excellent reliability for most domains with intraclass correlations (0.71-0.88; all P < 0.001). CONCLUSION: PSC PRO is a self-administered disease-specific instrument developed according to U.S. Food and Drug Administration guidelines. This preliminary validation study suggests good psychometric properties. Further validation of the instrument in a larger and more diverse sample of PSC patients is needed. (Hepatology 2018;68:155-165).
引用
- Younossi ZM, Afendy A, Stepanova M, et al. Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. Hepatology. 2018. PMID: 29152767. doi:10.1002/hep.29664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。